Biogen Idec’s Eloctate shows benefits in newly-published trial data

Biogen Idec has announced the publication of positive clinical trial data for Eloctate, the haemophilia A therapy it has developed alongside Swedish Orphan Biovitrum.

Detailed phase III data for the investigational long-lasting recombinant factor VIII Fc fusion protein candidate has been published in the medical journal Blood, revealing the benefits of once or twice-weekly prophylactic dosing regimens using the therapy.

Results from the A-LONG study showed that people with severe haemophilia A may achieve effective prevention or reduction of bleeding episodes with one or two prophylactic infusions a week, while the therapy was also associated with positive safety findings.

Dr Glenn Pierce, senior vice-president of global medical affairs and chief medical officer of Biogen Idec's haemophilia therapeutic area, said: "This study demonstrated the value of Fc fusion technology in prolonging factor half-life to make less frequent prophylactic infusions possible for people with haemophilia A."

This comes after the company published its financial results for the third quarter of 2013, highlighting a 32 percent year-on-year increase in revenues.